Combination therapy of Revlimid (lenalidomide) and Vidaza (azacitidine) was effective and well tolerated in high-risk myelodysplastic syndromes (MDS) patients, according to a Phase 1 study performed by United States researchers.
Vidaza is approved in the U.S. for all types of MDS patients, generally delays progression of MDS to acute myeloid leukemia, and improves overall survival. Revlimid is typically used to treat certain low- or intermediate-1 risk MDS patients.
The Phase 1 study results represented attempts by researchers to determine the…
Myelodysplastic syndromes (MDS) can represent a period of transition for a caregiver, but especially for the patient. As caregiver, you may be going through many of the same emotions as your loved one. This parallel experience can help you to understand, appreciate, and respond to your loved one’s emotions.
Changing Roles
As you become a caregiver, your family or relationship roles may be shifting. You may be assuming control of more responsibilities, and at the same time, your loved one…
Myelodysplastic syndromes (MDS)-related complications and progression to acute myelogenous leukemia (AML) are the leading cause of death for low- and intermediate-1 risk MDS patients, according to a report published in the journal Cancer. The most common complications include infection and bleeding.
In their study, the researchers sought to discover the cause of death in low-risk MDS patients where the disease had not progressed to AML in an attempt to guide early therapy decisions.
Currently, the exact cause of death in…
When caring for a loved one with myelodysplastic syndromes (MDS), feelings of loss and grief are natural. Although grief is often associated with the death of a loved one, grief can also be caused by loss of your loved one’s health as well as loss of freedom, control, finances, and plans for the future.
You may feel reluctant to examine or talk about your emotions associated with grief and loss through MDS. It may feel like acknowledging the loss as…